Last reviewed · How we verify
Orencia
At a glance
| Generic name | Orencia |
|---|---|
| Also known as | Abatacept |
| Sponsor | Bristol-Myers Squibb |
| Target | T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Juvenile idiopathic arthritis
- Rheumatoid arthritis
Common side effects
- Headache
- Nasopharyngitis
- Dizziness
- Cough
- Back pain
- Hypertension
- Dyspepsia
- Urinary tract infection
- Rash
- Pain in extremity
- Upper respiratory tract infection
- Sinusitis
Serious adverse events
- Serious infections
- Pneumonia
- Cellulitis
- Bronchitis
- Diverticulitis
- Acute pyelonephritis
- Malignancies
- Lung cancer
Key clinical trials
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (PHASE1)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- Study of COYA 302 for the Treatment of ALS (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBel (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Orencia CI brief — competitive landscape report
- Orencia updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI